Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00108-024-01708-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antiviral therapy for chronic hepatitis delta: new insights from clinical trials and real-life studies.
Gut
December 2024
D-SOLVE consortium, an EU Horizon Europe funded project (No 101057917), Hannover, Germany.
Chronic hepatitis D (CHD) is the most severe form of viral hepatitis, carrying a greater risk of developing cirrhosis and its complications. For decades, pegylated interferon alpha (PegIFN-α) has represented the only therapeutic option, with limited virological response rates and poor tolerability. In 2020, the European Medicines Agency approved bulevirtide (BLV) at 2 mg/day, an entry inhibitor of hepatitis B virus (HBV)/hepatitis delta virus (HDV), which proved to be safe and effective as a monotherapy for up to 144 weeks in clinical trials and real-life studies, including patients with cirrhosis.
View Article and Find Full Text PDFBulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48.
Liver Int
December 2024
Clinic for Gastroenterology, Hepatology, Infectious Diseases, and Endocrinology, Hannover Medical School, Hannover, Germany.
Article Synopsis
- The study assessed the safety and tolerability of bulevirtide (BLV), a new treatment for chronic hepatitis delta (CHD), by analyzing data from three clinical trials involving 269 patients.
- The findings indicated that certain adverse events, such as increased bile acid levels and injection-site reactions, were more common with BLV compared to a control group, but serious side effects were minimal and did not lead to treatment discontinuation.
- Overall, BLV was deemed safe and well tolerated over 48 weeks of therapy in patients with CHD, showing promise as an effective treatment option.
Bulevirtide Treatment of Hepatitis Delta Virus Infection in a Kidney Transplant Recipient: A Case Report.
Exp Clin Transplant
October 2024
From the Section of Infectious Diseases, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Objectives: Hepatitis delta virus infection poses a significant challenge in solid-organ transplant recipients due to its aggressive nature and limited therapeutic options. Bulevirtide is a novel antiviral agent approved by the European Medicines Agency in 2020 for the treatment of hepatitis delta virus infection, but limited data are available on its use in solid-organ transplant recipients.
Materials And Methods: We present a case report of a 42-year-old male kidney transplant patient with coinfection of hepatitis B virus and hepatitis delta virus who was treated with bulevirtide over a 6-month period.
The Culprit Behind HBV-Infected Hepatocytes: NTCP.
Drug Des Devel Ther
November 2024
Department of Infectious Diseases, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People's Republic of China.
Hepatitis B virus (HBV) is a globally prevalent human DNA virus responsible for over 250 million cases of chronic liver infections, leading to conditions such as liver inflammation, cirrhosis and hepatocellular carcinoma (HCC). Sodium taurocholate co-transporting polypeptide (NTCP) is a transmembrane protein highly expressed in human hepatocytes and functions as a bile acid (BA) transporter. NTCP has been identified as the receptor that HBV and its satellite virus, hepatitis delta virus (HDV), use to enter hepatocytes.
View Article and Find Full Text PDFReply to: "Optimising the treatment of HDV infection: Efficacy of bulevirtide, HBV-HDV interactions and the importance of statistical methods".
J Hepatol
October 2024
Gilead Sciences, Inc, Foster City, CA, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!